这段内容很关键，为了更好的理解原文，原文如下：Clarify if a BCS based biowaiver is only applicable for pharmaceutical equivalents. Furthermore, in case the Reference formulation or Comparator formulation is marketed with more than 1 strength, for example 10 and 20 mg IR release tablets, clarify whether the BCS based biowaiver should be matched 1 to 1, i.e., comparability should be shown between the 10 mg of the Reference/Comparator and 10 mg Test formulation and between the 20 mg of the Reference/Comparator and 20 mg Test formulation. Or is a full BCS based biowaiver sufficient for 1 strength and the other strength can be accepted based upon a biowaiver for additional strength.
